Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with B-precursor ALL in complete hematological remission after at least 3 intense chemotherapy blocks~* Presence of minimal residual disease at a level of ≥ 10\^-3~* Availability of bone marrow specimen from primary diagnosis for clone-specific MRD assessment~* Negative human immunodeficiency virus (HIV) test, negative hepatitis B (HbsAg) test and hepatitis C virus (anti-HCV) test~* Negative pregnancy test in women of childbearing potential~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion Criteria:~* Presence of circulating blasts or current extra-medullary involvement by ALL~* History of relevant central nervous system (CNS) pathology or current CNS pathology~* Prior allogeneic hematopoietic stem cell transplant (HSCT)~* Eligibility for treatment with tyrosine-kinase inhibitors (TKI)~* Systemic cancer chemotherapy within 2 weeks prior to study treatment~* Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment~* Previous treatment with blinatumomab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab (Type: EXPERIMENTAL): Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).